Semifluorinated Alkane Drug Class List

Drugs in Drug Class: Semifluorinated Alkane

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch And Lomb Inc	MIEBO	perfluorohexyloctane	SOLUTION/DROPS;OPHTHALMIC	216675-001	May 18, 2023		RX	Yes	Yes
Bausch And Lomb Inc	MIEBO	perfluorohexyloctane	SOLUTION/DROPS;OPHTHALMIC	216675-001	May 18, 2023		RX	Yes	Yes			Y
Bausch And Lomb Inc	MIEBO	perfluorohexyloctane	SOLUTION/DROPS;OPHTHALMIC	216675-001	May 18, 2023		RX	Yes	Yes
Bausch And Lomb Inc	MIEBO	perfluorohexyloctane	SOLUTION/DROPS;OPHTHALMIC	216675-001	May 18, 2023		RX	Yes	Yes

Market dynamics and patent landscape for drugs in the drug class: Semifluorinated alkane

Last updated: May 7, 2026

What counts as a “semifluorinated alkane” drug class in patents and markets?

In the context of drug products, “semifluorinated alkanes” usually refers to small-molecule, fluorine-containing aliphatic compounds where only part of the carbon-hydrogen framework is replaced by fluorine. Patent documents typically describe these as “semifluorinated” or “partially fluorinated” alkanes, fluorinated alkyls, fluorinated aliphatic chains, or “fluorinated fatty” and “fluorinated hydrocarbon” intermediates, depending on whether the end product is a standalone API or a substituent motif within a larger medicinal structure.

From a market-and-patent lens, the class splits into two commercial patterns:

• Standalone APIs where the semifluorinated alkane is the pharmacologically active scaffold (rare as a discrete, branded category).
• Chemistry motifs where semifluorinated or partially fluorinated alkanes are used to tune properties (solubility, permeability, metabolic stability, lung retention, or prodrug release). In these cases, the “drug class” is often market-visible through therapeutic indications, while the semifluorinated alkane wording appears as chemical structure descriptors in patents rather than as a branded class term.

Which drug products are most visible for semifluorinated alkane chemotypes?

The market visibility for semifluorinated alkanes is dominated by a limited set of branded or development-stage fluorinated-alkyl chemotypes, typically in local lung delivery, respiratory/inhaled anti-inflammatories or antimicrobials, and specialty oncology/supportive care where small changes in lipophilicity and stability drive performance.

However, a reliable, complete “market map” by product name requires explicit identification of the specific APIs that use semifluorinated alkane structures. With no named drug list in scope, the patent landscape cannot be mapped to product-specific filing networks without risking incorrect attribution.

What market dynamics drive investment and licensing in semifluorinated alkane programs?

Across fluorinated-lipid and partially fluorinated small-molecule development, the dominant commercial dynamics are consistent:

1. Delivery and formulation economics

   • Fluorinated aliphatic segments frequently correlate with improved membrane partitioning and altered solubility profiles, which affects inhalation suspension behavior, nebulization performance, and depot formation.
   • Product success tends to depend on formulation IP (compositions, particle engineering, delivery device integration) as much as on the core chemical IP.

2. Regulatory and manufacturing complexity

   • Partial fluorination often increases synthetic route complexity (protecting group strategy, fluorination steps, and impurity profiles).
   • Manufacturing cost and scale-up reliability drive partner selection and can shift “strategy value” from core compound patents toward process patents and control strategies.

3. Competition around therapeutic indication, not chemistry label

   • Investors underwrite by indication (respiratory, infectious disease, oncology supportive care) rather than by the chemical phrase “semifluorinated alkane.”
   • As a result, patent thickets are often built around use claims, dosing regimens, and formulation rather than the chemical term alone.

4. Life-cycle value: second-generation properties

   • A common dynamic is follow-on filings that adjust fluorination degree, chain length, or substitution pattern to improve exposure, tissue selectivity, or elimination half-life while preserving functional pharmacology.

How does the patent landscape typically structure around semifluorinated alkanes?

Semifluorinated alkane IP generally shows up in four layers, often interlocked:

• Core structure claims
  • Markush-style coverage of partially fluorinated alkyl substituents, with claims controlled by chain length (n), degree of fluorination (k), and substitution position.
• Synthesis and intermediates
  • Process claims covering fluorination methods, purification steps, and intermediate intermediates that are easier to enforce than broad final-product composition claims.
• Pharmaceutical composition claims
  • Excipients, particle size distributions, surfactant systems, and stabilization processes tailored to fluorinated compounds.
• Methods of treatment and use
  • Indication-specific claims (e.g., treating airway disease, reducing inflammatory markers, dosing schedules) that can sustain exclusivity even if a competing compound is chemically “near” but not literally within the core structure.

Where do you usually see claim scope differences versus competitors?

In semifluorinated alkane programs, scope differences tend to track the balance between:

• Chemical breadth (wide Markush ranges, broader substituent definitions)
• Functional boundaries (limitations tied to physicochemical parameters, such as partition coefficient proxies, viscosity window, solubility thresholds, or stability under storage)
• Use and device constraints (claims narrowed by administration route and delivery apparatus)

Competitors often challenge enforceability by designing around the chemical range while matching the functional profile, pushing litigation toward interpretation of Markush elements versus proving equivalence.

What does a “healthy” freedom-to-operate position look like in this space?

A robust FTO position typically requires checking that:

• The targeted semifluorinated alkane scaffold is not covered by Markush ranges spanning your intended fluorination degree and chain length.
• Composition claims do not capture your formulation system (surfactant and excipient selections, particle specs, and storage stability).
• Your planned route and dosing method does not fall within use claims that are tied to the same indication and patient subgroup.

How long is effective exclusivity and what does it usually include?

Semifluorinated alkane programs follow standard small-molecule exclusivity economics, but the IP mix tends to be more layered:

• Compound patent term: baseline chemical coverage
• Process patent term: additional protection if synthesis routes are distinct
• Formulation and method-of-treatment patents: multiple expiries staggered around development and regulatory milestones
• Orphan/conditional pathways (where applicable): can extend market protection beyond the earliest patent expiration through regulatory exclusivity mechanisms, depending on jurisdiction

What are the current patent landscape pressure points for semifluorinated alkane development?

The field’s pressure points are usually:

• Chemical design-around space is limited by enforceable breadth and close similarity of fluorination patterns.
• Formulation claims are the most litigation-prone because they can be enforced against generics that share excipient strategy but differ slightly in particle specs.
• Prosecution history matters: examiners often require narrow definitions for partially fluorinated substituent ranges, and those narrower elements become decisive in infringement analysis.

What strategies maximize IP defensibility for semifluorinated alkane programs?

Typical high-defensibility strategies:

• Build overlapping coverage across core compound, intermediates, and formulation so that a design-around must escape multiple independent claim families.
• Tie composition and method claims to route-specific clinical use and measurable quality attributes.
• File follow-ons around fluorination pattern optimization (chain length, substitution position, fluorination degree) with explicit data-supported parameter changes.

How should investors evaluate market traction in a semifluorinated alkane portfolio without relying on the chemical label?

Use indication-based traction metrics that correlate with fluorinated-alkyl advantages:

• Time on market and uptake by route (especially inhaled or localized delivery)
• Formulation platform repeatability across new molecules
• Partnering and co-development activity (often driven by manufacturing readiness and IP stacking rather than by early efficacy signals)

Key takeaways

• “Semifluorinated alkane” in patents is usually a chemical descriptor that appears across core structure, intermediates, compositions, and methods of treatment, not a stand-alone market category.
• Commercial performance is shaped by delivery/formulation economics and manufacturing complexity, which makes formulation and process IP disproportionately important.
• IP defensibility in this space depends on stacking coverage across chemistry + formulation + route-specific use, with Markush range breadth and narrowing events driving infringement risk.
• Without explicit drug/API identification, a complete product-by-product market and patent landscape cannot be mapped without risking incorrect inclusion.

FAQs

1. Are semifluorinated alkanes sold as a distinct drug class on formularies?
   Usually no; market visibility is typically organized by therapeutic indication and route while the semifluorinated alkane motif appears in chemical patents and formulation IP.

2. What type of patents most often extend exclusivity for fluorinated-alkyl drugs?
   Formulation, process, and method-of-treatment families often extend protection beyond the earliest compound grant because competitors can design around the final structure but may still face formulation and route-use claims.

3. Do semifluorinated alkane patents tend to be broad or narrow?
   Scope often starts broad (Markush) but becomes narrowed during prosecution around fluorination degree, chain length, and substitution position, so enforceability commonly hinges on those narrowed elements.

4. What is the most common competitor strategy?
   Design around the core scaffold range while keeping similar pharmacology and matching functional performance via formulation changes, which shifts disputes toward claim construction and formulation equivalence.

5. What is the most actionable diligence item for FTO?
   Verify whether planned compounds and formulations fall within (or avoid) the defined chemical range and whether your route, dosing regimen, and excipient system map onto existing composition and use claims.

References

[1] United States Patent and Trademark Office (USPTO). Patent Examination and related guidance (general). https://www.uspto.gov/
[2] European Patent Office (EPO). Guidelines for Examination (general patentability and claim scope conventions). https://www.epo.org/
[3] World Intellectual Property Organization (WIPO). Patent law and PCT resources (general frameworks). https://www.wipo.int/